Akrotome receives grant for the commercialization of a topical probe for margin determination in skin cancers
Akrotome Imaging has received a $1.77M SBIR Phase II grant to assist in the clinical translation of its FIRE™ probe for margin assessment in skin cancer.
In this application, FIRE is applied ex-vivo to skin tissue that has been surgically removed. When the probe detects cancer, it glows brightly, enabling the surgeon to see active cancer on or close to the margin of the sample.
Enabling rapid and global assessment of skin cancer margins, FIRE has the potential to reduce repeat surgeries by ensuring complete removal of all cancer while sparing healthy tissue.